Navigation Links
Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Date:3/25/2008

PALO ALTO, Calif., March 25 /PRNewswire/ -- Anacor Pharmaceuticals today announced results from a Phase 2a clinical trial of AN2728, an investigational topical anti-inflammatory drug, in patients with psoriasis. The study met its primary endpoint and all secondary endpoints.

In 69 percent of patients, the area treated with AN2728 scored better at the end of therapy than the area treated with the vehicle ointment, compared with six percent of patients in whom the vehicle-treated areas were superior. These results were statistically significant (p<0.001). No drug-related safety issues were reported.

"The results of this study suggest that AN2728 can effectively treat psoriasis in a clinical setting. In addition, plaques treated with AN2728 continued to improve over the course of the 28 days of therapy, suggesting longer-term treatment may have an even greater effect," said Karl R. Beutner, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Anacor. "These results are encouraging for both AN2728 and our entire anti-inflammatory program."

AN2728 is a novel boron-containing small molecule that inhibits the release of pro-inflammatory cytokines including TNF-alpha, IL-12, and IL-23, known mediators of the inflammation associated with psoriasis.

The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of an ointment containing a 5% concentration of AN2728 with patient self-application. Patients with psoriasis commonly have similar areas of psoriasis on their left and right, or front and back sides. The study took advantage of this bilateral characteristic of psoriasis. In this trial, 35 patients treated one of their areas of psoriasis with AN2728 ointment, and a matching area on the opposite side with vehicle alone, twice a day for four weeks.

In addition to this Phase 2a study, two Phase 1b dose-ranging trials have investigated the effects of concentration and formulation
'/>"/>

SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
2. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
3. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
4. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
5. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Ill. , July 7, 2015  Monopar Therapeutics ... oncology compounds, announced that its co-founder and CEO, ... British Council,s Education U.K. Alumni Entrepreneurial Award. The British ... China , India , and ... recognizes outstanding achievements made by entrepreneurs who have leveraged ...
(Date:7/7/2015)... SAN DIEGO , July 7, 2015 /PRNewswire/ ... pharmaceuticals, announced today initiation of enrollment and dosing ... clinical study of ABX-1431, a first-in-class, investigational endocannabinoid ... technology platform, which finds new small molecule drug ... of enzymes with important regulatory roles in human ...
(Date:7/7/2015)... NEW YORK , July 7, 2015  New ... treated with radiation therapy versus surgery for prostate ... University of Toronto presented their findings at the ... last month, which further suggest that prostate ... increased risk of requiring minimally invasive urologic procedures due ...
Breaking Medicine Technology:Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 2Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 3New Study Shows Surgery Has Less Side Effects and Long-Term Issues Over Radiation for Treating Prostate Cancer 2New Study Shows Surgery Has Less Side Effects and Long-Term Issues Over Radiation for Treating Prostate Cancer 3New Study Shows Surgery Has Less Side Effects and Long-Term Issues Over Radiation for Treating Prostate Cancer 4
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, today announced shareholder resolutions adopted at ... Kong on December 22, 2010. At the ... Ms. Joyce I-Yin Hsu and Mr. Wu Qiyao, each ...
... Inc. (Nasdaq: CEPH ) today announced that ... the U.S. Food and Drug Administration (FDA) for the ... [C-IV] for the treatment of patients with excessive sleepiness ...  In its letter to the company, the FDA reiterated ...
Cached Medicine Technology:Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder 2Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder 3
(Date:7/7/2015)... Annapolis, MD (PRWEB) , ... July 07, 2015 ... ... quality and an official accrediting body as designated by the Centers for Medicare ... improved user experience and to enhance compatibility with mobile devices. , The most ...
(Date:7/7/2015)... MO (PRWEB) , ... July 07, 2015 , ... ... liability law announce the launch of their new website, the Invokana Ketoacidosis ... Invokana FDA warning*, and serves as a resource for persons wishing to learn ...
(Date:7/7/2015)... ... July 07, 2015 , ... Clarion ... labels, has been featured in the latest issue of In Compliance Magazine, a ... In Compliance delivers the latest news, standards updates, technical explanations and guidance, ...
(Date:7/7/2015)... ... 07, 2015 , ... CareSync proudly announces today that Amy ... White House as a “Champion of Change” for Precision Medicine on Wednesday, July ... of Change program recognizes Gleason and eight other extraordinary individuals who are making ...
(Date:7/7/2015)... ... July 07, 2015 , ... Each year the ... charitable organizations on a local, national and international level; however, the Holiday Inn now ... will have a high impact on the beneficiaries. In September of 2014 they hosted ...
Breaking Medicine News(10 mins):Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3
... Aon Benfield, the world,s premier ... preliminary forecast of direct insured losses resulting from ... http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO )"While the maximum potential exposed insurance limits ... range of direct insured losses will be a ...
... Blue Foundation for a Healthy Florida , the philanthropic ... (BCBSF), has approved $761,000 in grants to be awarded ... services to in-need Floridians."Around 20 percent of Florida residents ... Blue Foundation for a Healthy Florida. "That,s more than ...
... RIVER EDGE, N.J., Jan. 14 Nephros, Inc. ... company developing and marketing filtration products for therapeutic ... that it has received notice from the NYSE ... or "AMEX" or the "Exchange"), regarding AMEX,s intention ...
... drugs in some cases , , WEDNESDAY, Jan. 14 (HealthDay News) ... antipsychotic drugs, used to treat conditions ranging from schizophrenia to ... to cardiac arrest. , The odds of a heart ... appropriate for certain patients. Still, doctors, families and patients should ...
... Jan. 14 The National Council of Legislators ... comprised of lawmakers from states with casinos and ... resolution Saturday encouraging states to take ... was adopted at the NCLGS 2009 Winter Meeting, ...
... January 14, 2009 - A new study suggests ... in the construction of artificial skin. The findings mark ... to pioneer a method of organ reconstruction. The study ... of the International Federation for Artificial Organs (IFAO), the ...
Cached Medicine News:Health News:Aon Benfield Forecasts Potential Impact on the Insurance Industry Resulting From the Alleged Madoff Scandal 2Health News:Florida's Uninsured and Underinsured to Benefit from Statewide Grants 2Health News:Nephros Receives Notice of Intention to Delist from AMEX 2Health News:Nephros Receives Notice of Intention to Delist from AMEX 3Health News:Nephros Receives Notice of Intention to Delist from AMEX 4Health News:Newer Antipsychotics Pose Cardiac Risk: Study 2Health News:National Council of Legislators From Gaming States Adopts Resolution Supporting 100% Smokefree Gaming Venues 2Health News:Study uses bone marrow stem cells to regenerate skin 2
... Titer Performance Panel consists of plasma specimens ... positive for antibodies to HTLV I and ... by manufacturers and diagnostic laboratories to evaluate ... all major test systems are included for ...
... Avaulta™ BioSynthetic Mesh is ... coated in the central ... hydrophilic film of porcine ... of the Avaulta™ BioSynthetic ...
Suspend® Tutoplast® Processed Fascia Lata is your naturally safe and strong choice for pelvic floor reconstruction. Suspend comes from a dense matrix of collagen bundles and transverse fasc...
... Bard® Dermal Allograft ... of most pelvic floor ... highly resistant to suture ... and serves as a ...
Medicine Products: